BioWorld

Feb. 4, 2005

View Archived Issues

Valeant Buying Out Xcel's Neurology Line For $280M

About this time last year, Xcel Pharmaceuticals Inc. bought the rights to the Phase III-ready epilepsy drug retigabine from Viatris GmbH and Co., of Frankfurt, Germany. (BioWorld Today) Read More

Bioenvision Brings In $60M; Favrille, Icagen Make Debuts

Read More

Myogen's Stock Drops On Delay In Ambrisentan Trial

Read More

Xcyte's Shares Slump As FDA Seeks To Rework Trial Plans

Read More

Other News To Note

Read More